364 related articles for article (PubMed ID: 20540746)
1. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.
Liu YY; Gupta V; Patwardhan GA; Bhinge K; Zhao Y; Bao J; Mehendale H; Cabot MC; Li YT; Jazwinski SM
Mol Cancer; 2010 Jun; 9():145. PubMed ID: 20540746
[TBL] [Abstract][Full Text] [Related]
2. A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis.
Patwardhan GA; Zhang QJ; Yin D; Gupta V; Bao J; Senkal CE; Ogretmen B; Cabot MC; Shah GV; Sylvester PW; Jazwinski SM; Liu YY
PLoS One; 2009 Sep; 4(9):e6938. PubMed ID: 19742320
[TBL] [Abstract][Full Text] [Related]
3. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
[TBL] [Abstract][Full Text] [Related]
4. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance.
Liu YY; Han TY; Giuliano AE; Hansen N; Cabot MC
J Biol Chem; 2000 Mar; 275(10):7138-43. PubMed ID: 10702281
[TBL] [Abstract][Full Text] [Related]
5. Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells.
Siddiqui A; Patwardhan GA; Liu YY; Nazzal S
Int J Pharm; 2010 Nov; 400(1-2):251-9. PubMed ID: 20816930
[TBL] [Abstract][Full Text] [Related]
6. Co-suppression of MDR1 (multidrug resistance 1) and GCS (glucosylceramide synthase) restores sensitivity to multidrug resistance breast cancer cells by RNA interference (RNAi).
Zhang X; Li J; Qiu Z; Gao P; Wu X; Zhou G
Cancer Biol Ther; 2009 Jun; 8(12):1117-21. PubMed ID: 19502811
[TBL] [Abstract][Full Text] [Related]
7. The effect of glucosylceramide synthase on P-glycoprotein function in K562/AO2 leukemia drug-resistance cell line.
Zhang YY; Xie KM; Yang GQ; Mu HJ; Yin Y; Zhang B; Xie P
Int J Hematol; 2011 Mar; 93(3):361-367. PubMed ID: 21380926
[TBL] [Abstract][Full Text] [Related]
8. Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells.
Liu YY; Han TY; Yu JY; Bitterman A; Le A; Giuliano AE; Cabot MC
J Lipid Res; 2004 May; 45(5):933-40. PubMed ID: 14967819
[TBL] [Abstract][Full Text] [Related]
9. Gb3-cSrc complex in glycosphingolipid-enriched microdomains contributes to the expression of p53 mutant protein and cancer drug resistance via β-catenin-activated RNA methylation.
Roy KR; Uddin MB; Roy SC; Hill RA; Marshall J; Li YT; Chamcheu JC; Lu H; Liu YY
FASEB Bioadv; 2020 Nov; 2(11):653-667. PubMed ID: 33205006
[TBL] [Abstract][Full Text] [Related]
10. Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.
Liu YY; Hill RA; Li YT
Adv Cancer Res; 2013; 117():59-89. PubMed ID: 23290777
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog.
De Rosa MF; Ackerley C; Wang B; Ito S; Clarke DM; Lingwood C
J Biol Chem; 2008 Feb; 283(8):4501-11. PubMed ID: 18003606
[TBL] [Abstract][Full Text] [Related]
12. Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells.
Kanagasabai R; Krishnamurthy K; Druhan LJ; Ilangovan G
J Biol Chem; 2011 Sep; 286(38):33289-300. PubMed ID: 21784846
[TBL] [Abstract][Full Text] [Related]
13. Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation.
Kim HG; Hien TT; Han EH; Hwang YP; Choi JH; Kang KW; Kwon KI; Kim BH; Kim SK; Song GY; Jeong TC; Jeong HG
Br J Pharmacol; 2011 Mar; 162(5):1096-108. PubMed ID: 21054339
[TBL] [Abstract][Full Text] [Related]
14. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y
Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1/P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation.
Wang YH; Imai Y; Shiseki M; Tanaka J; Motoji T
Leuk Res; 2018 Apr; 67():99-108. PubMed ID: 29482174
[TBL] [Abstract][Full Text] [Related]
16. Ceramide glycosylation by glucosylceramide synthase selectively maintains the properties of breast cancer stem cells.
Gupta V; Bhinge KN; Hosain SB; Xiong K; Gu X; Shi R; Ho MY; Khoo KH; Li SC; Li YT; Ambudkar SV; Jazwinski SM; Liu YY
J Biol Chem; 2012 Oct; 287(44):37195-205. PubMed ID: 22936806
[TBL] [Abstract][Full Text] [Related]
17. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
Gouazé V; Liu YY; Prickett CS; Yu JY; Giuliano AE; Cabot MC
Cancer Res; 2005 May; 65(9):3861-7. PubMed ID: 15867385
[TBL] [Abstract][Full Text] [Related]
18. Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells.
Gouazé-Andersson V; Yu JY; Kreitenberg AJ; Bielawska A; Giuliano AE; Cabot MC
Biochim Biophys Acta; 2007 Dec; 1771(12):1407-17. PubMed ID: 18035065
[TBL] [Abstract][Full Text] [Related]
19. UDP-glucose ceramide glucosyltransferase activates AKT, promoted proliferation, and doxorubicin resistance in breast cancer cells.
Wegner MS; Schömel N; Gruber L; Örtel SB; Kjellberg MA; Mattjus P; Kurz J; Trautmann S; Peng B; Wegner M; Kaulich M; Ahrends R; Geisslinger G; Grösch S
Cell Mol Life Sci; 2018 Sep; 75(18):3393-3410. PubMed ID: 29549423
[TBL] [Abstract][Full Text] [Related]
20. CBP-dependent Wnt/β-catenin signaling is crucial in regulation of MDR1 transcription.
Xia Z; Guo M; Liu H; Jiang L; Li Q; Peng J; Li JD; Shan B; Feng P; Ma H
Curr Cancer Drug Targets; 2015; 15(6):519-32. PubMed ID: 25968898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
